Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalated Adaptive RadioTherapy in Definitive Chemo-radiotherapy for Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patients must meet all of the following inclusion criteria to be included in the study:~* Patients with histologically verified squamous cell or adenocarcinoma (including signet cell carcinoma) of the oesophagus or GEJ.~* Multi-Disciplinary Team (MDT) assessment and treatment recommendation; deemed nonresectable and/or inoperable.~* TNM stage (8th edition): cT1-4a or cN+, cM0-1 (M1 disease limited to metastatic lymph nodes)~* Age ≥18 years.~* Performance status ≤2.~* Adequate cardiac, lung and renal function measured according to local guidelines.~* Adequate laboratory findings:~  * haematological: haemoglobin \> 90 g/L, absolute neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 75 x 109/L~ * hepatic: bilirubin ≤ 1.5 x ULN, ALAT ≤ 3 x ULN~ * renal: creatinine ≤ 1.5 x ULN~* Suitability to undergo curatively intended chemoradiation therapy.~* Ability to adhere to procedures for study and follow-up.~* Women must present a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use oral contraceptives, intrauterine devices, depot injection of progestin subdermal implantation, a hormonal vaginal ring, or transdermal patch during the study treatment and one month after.~* Signed informed consent to participate in the study, including acceptance that dose plan and scans will be stored in a national dose plan bank, and the remaining data stored in a central database.~* A standard plan for radiotherapy with homogenous 50 Gy / 25 fractions, meeting all dose constraints for normal tissue, must be achievable.~Exclusion Criteria:~Patients who will meet one or more of the following exclusion criteria cannot be included in this study:~* Prior oncological treatment or surgical resection for the present disease~* Broncho-pulmonary fistula verified by bronchoscopy~* Any other active malignancies which may compromise study protocol or endpoints except for basal or squamous cell skin cancer~* Any unstable systemic disease (including clinically significant cardiovascular disease, unstable angina, New York Heart Association (NYHA) grade III-IV congestive heart, severe hepatic, renal or metabolic disease or active inflammatory bowel disease)~* Symptomatic peripheral neuropathy greater than grade 1 (CTCAE version 4.03)~* Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial~* Severely decreased lung function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation Arm (Type: EXPERIMENTAL): Chemo-radiotherapy with radiotherapy dose escalation based on Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG/PET) scans
- Standard (Type: NO_INTERVENTION): Standard chemo-radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues